Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Last December, Pfizer (NYSE: PFE) essentially out-licensed its tumor necrosis factor-like ligand 1A (TL1A), PF-06480605 (now RVT-3101), to Roivant Sciences (NASDAQ: ROIV) by forming a new company with the precision drugmaker. Per the terms of the deal Pfizer owns a 25% equity sta
:max_bytes(150000):strip_icc():format(jpeg)/PropertyValuation-4ecdfe3a87144fe998087ef433f49c13.jpeg "Is There a Gender Gap in Home Equity Loans?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1346781100-2724c28da6b2479b88db9d1337ebe926.jpg "Buy Now, Pay Later or Rent-to-Own: Which Is the Smarter Way to Pay for Purchases?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1917868586-d64880817bca4098bc8be36bbd17a4e9.jpg "Should You Trade Options on Spot Bitcoin ETFs?")